Amarin sales of Vascepa 'could take off soon,' says Cantor FitzgeraldCantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin with a $35 price target. The analyst continues to think that the peak sales opportunity for Vascepa, post positive Reduce-It results, is still underappreciated. Prescriptions for Vascepa continue to accelerate post the positive results and Q4 has historically been Amarin's best quarter of the year, Chen tells investors in a research note titled "Buckle Up, Because Vascepa Rxs Could Take Off Soon."Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Tiger's Take: "This maybe a good buying opportunity, the volatility here has been as traders can't agree on what this drug's potential sales realy will be". $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.